ARTICLE | Company News
FDA to review Aveo's tivozanib
November 29, 2012 1:57 AM UTC
Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) and partner Astellas Pharma Inc. (Tokyo:4503) said FDA accepted for review an NDA for Tivopath tivozanib to treat renal cell carcinoma (RCC). FDA did not grant ...